Editor-in-Chief & Deputy Editor 2019-2021

 

Editor-in-Chief:

Nicolas LANTHIER

 

Deputy Editor:

Tim VANUYTSEL

 

More news.

Sponsors & Partners



Acta Gastroenterologica Belgica is supported by grants from its major sponsors

 

Acta Gastroenterologica Belgica is supported by grants

from its major sponsors

Dr Falk Pharma

 

 

 

 

 

 

Acta Gastro-Enterologica Belgica is published in

partnership with the following national societies


 

 

 

 

 

SRBGE

 

Archive List
Volume 82 - 2019 Volume 81 - 2018 Volume 80 - 2017 Volume 79 - 2016 Volume 78 - 2015 Volume 77 - 2014 Volume 76 - 2013    Fasc.1, January-March 2013       Reviews       Original articles       Georges Brohée Prize       Case Reports       Letters Volume 75 - 2012 Volume 74 - 2011 Volume 73 - 2010 Volume 72 - 2009 Volume 71 - 2008 Volume 70 - 2007 Volume 69 - 2006 Volume 68 - 2005 Volume 67 - 2004 Volume 66 - 2003 Volume 65 - 2002 Volume 64 - 2001 Volume 63 - 2000 Volume 62 - 1999 Volume 61 - 1998
Download Area

Georges Brohée Prize


Towards a tailored therapy in pancreatic cancer


Price: €10,00

Pancreatic ductal adenocarcinoma (PDAC) remains a major unsolved health problem. As conventional treatments have shown only a modest impact on disease course, development of new therapeutic strategies based on the molecular biology of PDAC must be a high priority. The identification of relevant predictive and prognostic biomarkers which can be used to select patient subgroups that may benefit from conventional treatments and new targeted agents will be of considerable interest. We have demonstrated the ability of the metabolizing gemcitabine protein (the human Equilibrative nucleoside transporter 1 and the deoxycytidine kinase) in predicting the benefit of adjuvant gemcitabine-based therapy in resected PDAC patients. Beside these predictive biomarkers, we have evaluated different molecular factors that may impact on the likely course of this cancer. The chemokine receptor CXCR4 that has been shown to be implicated in PDAC tumorigenicity and aggressiveness could serve as a prognostic marker for survival after a curative-intent surgery and was associated with the pattern of tumour recurrence (distant versus local relapse). Our findings were validated in an independent cohort of patients. Overall our results suggested that (i) the benefit of an adjuvant gemcitabinebased therapy can be predicted based on the tumour expression of hENT1 and dCK, (ii) CXCR4 is an independent negative prognostic factor and an independent predictor of distant relapse suggesting that anti-CXCR4 targeting therapies can be a promising treatment in combination with cytotoxic chemotherapy in the adjuvant setting. These data open new perspectives for designing trials based on a molecular driven strategy. (Acta gastroenterol. belg., 2013, 76, 49-56). [Product Details...]